The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.
Search results for: pediatric
Washington Pediatric Rheumatologists Eligible for Loan Forgiveness
The 2021–23 Washington budget enables consideration of pediatric rheumatologists for state loan forgiveness programs during the 2019–21 and 2021–23 cycles, making it the first state to include any rheumatologists in its loan forgiveness programs.
Updates in Pediatric Lupus: Experts Discuss Advances in Lupus Nephritis Treatments, Monogenic Lupus & More
PRSYM—At the 2021 Pediatric Rheumatology Symposium (PRSYM), a session on lupus provided a robust discussion of recent advances in lupus treatments and genetic discoveries in pediatric rheumatology. Lupus Nephritis The first speaker was Shaun Jackson, MD, PhD, a pediatric nephrologist and rheumatologist and associate professor at Seattle Children’s. His presentation focused on state-of-the-art treatments in…
Achieving Excellence in Pediatric Rheumatology Clinical Care
PRSYM—At its heart, the practice of medicine in all forms is specifically centered on delivering compassionate, thoughtful and evidence-based clinical care. In the world of pediatric rheumatology, a range of issues, such as chronic pain, reproductive health and transitioning to adult providers, are of utmost importance to patients and physicians alike. These topics were addressed…
Case Report: Digital Ulcers & Weight Loss in a Pediatric Patient
Juvenile dermatomyositis (JDM) is a childhood form of inflammatory myopathy affecting children younger than 18 years. The diagnosis of JDM is based on characteristic clinical features of proximal muscle weakness, skin rash, elevated muscle enzymes, magnetic resonance imaging and muscle biopsy.1 Autoantibodies seen in patients with inflammatory myopathy are not only associated with particular phenotypes…
A Team Approach Improves the Transition from Pediatric to Adult Care
Nearly all adolescents and young adults (AYAs) with chronic pediatric rheumatic disease require transfer of care to an adult rheumatologist, yet almost half are lost from care at the time of transfer.1-3 Although sometimes framed as a discrete event, transition refers to the longitudinal process, often spanning several years, in which AYAs and their families…
A Lack of Pediatric Providers Can Have Long-Term Consequences
As with rheumatology care in general, the current demand for pediatric rheumatologists is greater than the supply of providers available. That imbalance is expected to increase significantly by 2030 unless action is taken, according to a new workforce study published in Arthritis Care & Research.1 The lack of pediatric providers is a serious problem that…
Pediatric Rheumatology Workforce Challenges in the Dakotas
Pediatric rheumatologists are few and far between in rural America. Financial incentives, such as loan repayment, may help draw more providers to the subspecialty and the underserved regions of the U.S.
ACR, Coalition Ask Congress to Fund Pediatric Subspecialty Loan Repayment Program
The ACR has joined with a coalition of organizations dedicated to improving the health and wellbeing of children and adolescents to request $50 million to fund the Pediatric Subspecialty Loan Repayment Program.
2020 Pediatric Rheumatology Research in Review
ACR CONVERGENCE 2020—This has been a busy year for research publications covering a number of pediatric rheumatic diseases, including the emerging multi-system inflammatory syndrome (MIS-C) associated with SARS CoV-2. Despite the many challenges brought about by the COVID-19 pandemic, a healthy collection of publications covering a wide range of pediatric rheumatology research topics were published…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 111
- Next Page »